Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.4 -0.1  -1.3%

Last Trade - 20/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £67.6m
Enterprise Value £3.92m
Revenue £n/a
Position in Universe 5180th / 6848

BUZZ-Street View: Failure of Aprea's cancer treatment quashes remaining bullish sentiments

Tue 29th December, 2020 3:53pm
** Drug developer's  APRE.O  lead drug candidate,
eprenetapopt, in combination with chemotherapy drug azacitidine,
did not meet the main goal of complete remission (CR) in a
late-stage trial in patients with myelodysplastic syndrome
(MDS), a type of blood cancer
    ** At least five brokerages cut PT
    
    "TRIAL FAILURE IS BAD, ROAD AHEAD MAY BE WORSE"
    
    ** Berenberg Capital Markets("buy", PT: $10) lowers
probability of success of the drug in MDS to 10% from 68% but
continues to have positive view of the mechanism of action
employed by eprenetapopt
    ** Baird ("neutral", PT: $5) says while some level of
underperformance was anticipated, a drop of 33% in CR suggests
there is really no chance of success in future analyses of this
trial
    ** Adding that current trial failure makes it difficult to
believe the drug will suceed in additional indications and sees
it as a repudiation of APRE's approach to cancer treatment
    ** H.C.Wainwright ("neutral", PT: $6) says trial failure
adds to its already negative view of APRE's cancer program which
was shaped by safety concerns, competitors gaining market share
and APRE not owning or licensing any patents for eprenetapopt
    ** Brokerage to remain on sidelines until further
proof-of-concept data is presented on efficacy and working of
APRE's approach to cancer treatment that involves p53 gene
reactivation

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.